Calidi Biotherapeutics, Inc. Cash and Cash Equivalents, Fair Value Disclosure
Calidi Biotherapeutics, Inc. (CLDI) had Cash and Cash Equivalents, Fair Value Disclosure of $218.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2024-03-15
- 2023-12-31: Cash and Cash Equivalents, Fair Value Disclosure $218.00K.
- 2023-09-30: Cash and Cash Equivalents, Fair Value Disclosure $218.00K.
- 2022-12-31: Cash and Cash Equivalents, Fair Value Disclosure $218.00K.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2023-12-31 | $218.00K 10-K · filed 2024-03-15 |
| 2023-09-30 | $218.00K 10-Q · filed 2023-11-14 |
| 2022-12-31 | $218.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |